U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07309211) titled 'Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT' on Dec. 01.
Brief Summary: This is a retrospective, multi-centre, single arm study to assess the safety and efficacy of receiving Durvalumab in patients with Small Cell Lung Cancer Limited Stage (LS-SCLC) who have not progressed following sequential chemoradiotherapy (sCRT) in a real-world setting. The study will enroll 25 patients. The primary endpoint of the study is the incidence of Grade 3 or 4 adverse events (AEs) within 6 months of starting Durvalumab (graded by CTCAE v.5.0). The secondary endpoints of the study include real-world progression-free sur...